|
|
-
2013 Conference on Retroviruses and Opportunistic Infections*
March 3-6, 2013
| Atlanta, Georgia
Join expert faculty members Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; William G. Powderly, MD; Kimberly Y. Smith, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, for a review of the HIV highlights of this important annual conference.
-
In this CME-certified slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review the most clinically relevant data presented at the 2013 Conference on Retroviruses and Opportunistic Infections.
-
In this downloadable slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review key studies on coinfection and comorbidities in HIV infection from the 2013 Conference on Retroviruses and Opportunistic Infections.
-
Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, highlight the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.
Latest Content
-
Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, comment on the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.
Faculty: Joel E. Gallant MD, MPH, Kathleen E. Squires MD, Andrew R. Zolopa MD
Released: 5/7/2013
-
In this CME-certified slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review the most clinically relevant data presented at the 2013 Conference on Retroviruses and Opportunistic Infections.
Faculty: Joseph J. Eron, Jr. MD, William G. Powderly MD, Kimberly Y. Smith MD, MPH
Released: 5/3/2013
-
In this downloadable slideset, Joseph J. Eron, Jr., MD; William G. Powderly, MD; and Kimberly Y. Smith, MD, MPH, review key studies on coinfection and comorbidities in HIV infection from the 2013 Conference on Retroviruses and Opportunistic Infections.
Date Posted: 3/22/2013
-
Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, highlight the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.
Date Posted: 3/21/2013
-
High incidence of early deaths in patients initiating first-line ART during antifungal induction therapy for CM vs deferring ART until ≥ 5 weeks after CM diagnosis.
Date Posted: 3/14/2013
-
Few differences reported from subset analyses of 2 phase III trials including efficacy and discontinuation rates of dolutegravir-based regimens compared with efavirenz- and raltegravir-based regimens
Date Posted: 3/13/2013
-
Randomized noninferiority study in patients with PI, NNRTI, and NRTI experience and/or viral resistance suggests that NRTIs may be safely omitted from a new optimized regimen without compromising efficacy.
Date Posted: 3/12/2013
-
Both doses of MK-1439 monotherapy tested in the study produced similar > 1 log10 decreases in HIV-1 RNA over 7 days.
Date Posted: 3/12/2013
-
SVR8 attained by 93% to 96% of patients in the 12-week arms; both regimens safe and generally well tolerated, with anemia and grade 3/4 bilirubin increases in the RBV-containing treatment arms only.
Date Posted: 3/10/2013
-
In this small dose-finding study, rifampin doses up to 35 mg/kg were safe, well tolerated, and more active than the currently used 10-mg/kg dose in patients with newly diagnosed TB.
Date Posted: 3/10/2013
|
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|